Differential treatment effect on overall survival (OS) based on early prostate-specific antigen (PSA) response in metastatic hormone-sensitive prostate cancer (mHSPC): A secondary analysis of TITAN trial.

被引：0
|
作者：
Roy, Soumyajit
Malone, Shawn
Sun, Yilun
Wallis, Christopher J. D.
Kishan, Amar Upadhyaya
Morgan, Scott C.
Gebrael, Georges
Swami, Umang
Jia, Angela
Brown, Jason R.
Saad, Fred
Agarwal, Neeraj
Spratt, Daniel Eidelberg
机构：
[1] Rush Univ, Med Ctr, Chicago, IL USA
[2] Univ Ottawa, Ottawa Hosp, Ottawa, ON, Canada
[3] Case Western Reserve Univ, Cleveland, OH USA
[4] Mt Sinai Hosp, Div Urol, Toronto, ON, Canada
[5] Univ Calif Los Angeles, Dept Radiat Oncol, Los Angeles, CA USA
[6] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[7] Univ Hosp Seidman Canc Ctr, Cleveland, OH USA
[8] Ctr Hosp Univ Montreal, Montreal, PQ, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
261-436-2730; 613-135-2370-7650-2700; 283-2494-5577-5578; 261-492-5651-9271; 8; 6; 2; 1917; 1;
D O I：
10.1200/JCO.2024.42.4_suppl.126
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：126 / 126
页数：1
相关论文
共 50 条
  • [1] Association of prostate-specific antigen (PSA) response and overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase 3 ARASENS trial.
    Saad, Fred
    Hussain, Maha H. A.
    Tombal, Bertrand F.
    Fizazi, Karim
    Sternberg, Cora N.
    Crawford, E. David
    Thiele, Silke
    Li, Rui
    Kuss, Iris
    Joensuu, Heikki
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Assessing PSA levels as prognostic of overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC)
    Halabi, Susan
    Roy, Akash
    Guo, Siyuan S.
    Rydzewska, Larysa
    Godolphin, Peter
    Hussain, Maha H. A.
    Tangen, Catherine
    Thompson, Ian
    Xie, Wanling
    Carducci, Michael Anthony
    Smith, Matthew Raymond
    Morris, Michael J.
    Gravis, Gwenaelle
    Dearnaley, David P.
    Verhagen, Paul
    Goto, Takayuki
    Tierney, Jayne F.
    James, Nicholas D.
    Buyse, Marc E.
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] TITAN study: evaluation of apalutamide in patients with metastatic hormone-sensitive prostate cancer - Treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
    Merseburger, Axel S.
    Suttmann, Henrik
    AKTUELLE UROLOGIE, 2021, 52 (02) : 155 - 160
  • [4] Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer
    Myint, Zin W.
    Kolesar, Jill M.
    McCorkle, Joseph Robert
    Wu, Jianrong
    Ellis, Carleton S.
    Otto, Danielle E.
    Wang, Peng
    MEDICAL SCIENCE MONITOR, 2022, 28
  • [5] Radiographic progression in the absence of prostate-specific antigen (PSA) progression in patients with metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analysis of ARCHES.
    Armstrong, Andrew J.
    Mottet, Nicolas
    Iguchi, Taro
    Szmulewitz, Russell Zelig
    Holzbeierlein, Jeffrey
    Villers, Arnauld
    Alcaraz, Antonio
    Alekseev, Boris
    Shore, Neal D.
    Gomez-Veiga, Francisco
    Rosbrook, Brad
    Zohren, Fabian
    Lee, Ho-Jin
    Haas, Gabriel P.
    Stenzl, Arnulf
    Azad, Arun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Clinical outcomes of patients with metastatic Hormone-Sensitive Prostate Cancer (mHSPC) with Prostate-Specific Antigen (PSA) decline to undetectable levels on enzalutamide (ENZA): Post hoc analysis of ARCHES
    Stenzl, A.
    Shore, N. D.
    Villers, A.
    Iguchi, T.
    Gomez-Veiga, F.
    Alcaraz, A.
    Alekseev, B.
    Azad, A. A.
    Szmulewitz, R. Z.
    Petrylak, D.
    Holzbeierlein, J.
    Rosbrook, B.
    Zohren, F.
    Haas, G. P.
    Gourgioti, G.
    El-Chaar, N. N.
    Armstrong, A. J.
    EUROPEAN UROLOGY, 2022, 81 : S776 - S777
  • [7] Intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC)
    Halabi, S.
    Roy, A.
    Rydzewska, L.
    Godolphin, P.
    Parmar, M. K.
    Hussain, M.
    Tangen, C.
    Thompson, I. M.
    Xie, W.
    Carducci, M. A.
    Smith, M.
    Morris, M. J.
    Mescam, G. Gravis
    Dearnaley, D.
    Verhagen, P.
    Goto, T.
    James, N. D.
    Buyse, M. E.
    Tierney, J.
    Sweeney, C. J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1171 - S1171
  • [8] Assessing intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC).
    Halabi, Susan
    Roy, Akash
    Rydzewska, Larysa
    Godolphin, Peter
    Parmar, Mahesh K. B.
    Hussain, Maha H. A.
    Tangen, Catherine
    Thompson, Ian
    Xie, Wanling
    Carducci, Michael Anthony
    Smith, Matthew Raymond
    Morris, Michael J.
    Gravis, Gwenaelle
    Dearnaley, David P.
    Verhagen, Paul
    Goto, Takayuki
    James, Nicholas D.
    Buyse, Marc E.
    Tierney, Jayne F.
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] Prostate-specific antigen value at 3 & 7 months (PSA-3mo, PSA-7mo) and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation (ADT) with or without orteronel (SWOG S1216)
    Parikh, Mamta
    Tangen, Catherine
    Hussain, Maha H. A.
    Gupta, Shilpa
    Jo, Yeonjung
    Harzstark, Andrea
    Paller, Channing Judith
    George, Saby
    Zibelman, Matthew R.
    Cheng, Heather H.
    Maughan, Benjamin L.
    Zhang, Jingsong
    Pachynski, Russell Kent
    Bryce, Alan Haruo
    Lin, Daniel W.
    Quinn, David I.
    Thompson, Ian M.
    Dorff, Tanya B.
    Lara, Primo N.
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer
    Nakanishi, Shotaro
    Goya, Masato
    Tamaki, Mitsuyoshi
    Oshiro, Takuma
    Saito, Seiichi
    BMC RESEARCH NOTES, 2021, 14 (01)
12345